Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Download PDF: Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Articles in this issue

over 17 years ago

Article

Beyond LDL Cholesterol: The Role of Elevated Triglycerides and Low HDL Cholesterol in Residual CVD Risk Remaining After Statin Therapy

over 17 years ago

Article

Introduction

over 17 years ago

Article

Participating Faculty

over 17 years ago

Article

The Impact of Residual CVD Risk in the Managed Care Setting

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD